Wogonin

Mechanism of Action: Wogonin can help customers examine natural-product effects on proteostasis, autophagy, oxidative stress, and inflammatory signaling. It is suitable for studies assessing whether flavonoid-mediated pathway modulation enhances turnover of stress-regulated, unstable, or aggregation-prone proteins through proteasome- or lysosome-associated mechanisms.

• PROTAC Ligand for Degradation: Wogonin can be used as a small-molecule binding module within PROTAC designs to recruit an E3 ligase and drive selective degradation of a chosen target protein. By tuning linker length and attachment position, researchers can optimize ternary complex formation, ubiquitination efficiency, and degradation potency across cell-based assays.

• Target Validation via PROTACs: Wogonin-based PROTACs are suitable for systematic target validation, enabling researchers to distinguish degradation-dependent phenotypes from occupancy effects. Comparing PROTAC-treated cells with matched control constructs (non-degrading variants or E3-binding-deficient analogs) helps confirm that observed pathway modulation results from targeted proteolysis.

• Linker Optimization and Tuning: Incorporating Wogonin into PROTAC architectures supports structure–function studies aimed at improving degradation kinetics. Systematic variation of linker chemistry and geometry can enhance proximity between target and E3 ligase, increasing ubiquitin transfer and promoting sustained loss of target protein levels.

• Mechanistic Studies of Ubiquitination: Wogonin-containing PROTACs can be leveraged to probe the mechanistic steps of targeted protein degradation. Researchers can quantify ubiquitination, assess dependence on specific E3 ligase machinery, and evaluate how changes in Wogonin engagement influence ternary complex stability and downstream proteasome-mediated turnover.

Structure: The structure of Wogonin is characterized by phenol or alcohol functionality. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The hydroxy or phenolic motif can be considered for ether, carbonate, carbamate, or ester linker attachment after SAR verification. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.